Literature DB >> 6207159

Enhanced antitumor activity of mitomycin C conjugated with anti-alpha-fetoprotein antibody by a novel method of conjugation.

Y Kato, Y Tsukada, T Hara, H Hirai.   

Abstract

Mitomycin C (MMC) was conjugated to horse anti-rat alpha-fetoprotein (AFP) antibody at the N-1a position through a glutaric acid-derived spacer arm. In vitro studies showed that MMC was spontaneously and slowly released from the conjugate. The conjugate caused a greater inhibition of both the in vitro and in vivo tumor growth of the AFP-producing rat hepatoma AH66 than did a mixture of anti-rat AFP antibody and MMC or a similar conjugate of MMC with normal horse immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6207159

Source DB:  PubMed          Journal:  J Appl Biochem        ISSN: 0161-7354


  4 in total

1.  Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human alpha-fetoprotein conjugated with mitomycin C via human serum albumin.

Authors:  K Ohkawa; Y Tsukada; N Hibi; N Umemoto; T Hara
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 2.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

3.  Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.

Authors:  K Ohkawa; T Hatano; Y Tsukada; M Matsuda
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

4.  Suppression of human alpha-foetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti alpha-foetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier.

Authors:  Y Tsukada; K Ohkawa; N Hibi
Journal:  Br J Cancer       Date:  1985-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.